Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Portugal Uses Horizon Scanning To Speed Up Market Entry For Innovative Drugs

Executive Summary

Portugal’s medicines regulator, Infarmed, wants to prioritize new medicines and speed up access to innovation with a new horizon scanning initiative.

You may also be interested in...

EFPIA Works To Get Industry View Included In Horizon Scanning Initiatives

The European Federation of Pharmaceutical Industries and Associations is preparing its principles on horizon scanning.

How To Make Collaborative HTA Work In Europe: A Guide From EUnetHTA

A new report from the European HTA network Collaboration on health technology assessments and joint work, such as relative effectiveness assessments, will better succeed if they fit with member state procedures, according to an analysis from the European Network for Health Technology Assessment.

BeNeLuxA Medicine Access Collaboration Plans Joint Horizon Scanning

Belgium, the Netherlands, Luxemburg and Austria are continuing their collaboration on improving access to medicines and are finalizing a proposal on a joint horizon scanning initiative.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts